Literature DB >> 32355522

MicroRNA-21 depletion by CRISPR/Cas9 in CNE2 nasopharyngeal cells hinders proliferation and induces apoptosis by targeting the PI3K/AKT/MOTOR signaling pathway.

Zhenzhou Xiao1, Yan Chen1, Zhaolei Cui1.   

Abstract

BACKGROUND: We assess the effects exerted by CRISPR/Cas9 mediated microRNA 21 (miR-21) depletion on the biologic characteristics of CNE2 nasopharyngeal carcinoma (NPC) cells and the underlying mechanisms.
METHODS: The sgRNA was designed targeted at miR-21 gene, along with the construction of the CRISPR/Cas9 lentivirus system and the detection of editing efficiency through T7EN1 enzyme digestion. Effects of miR-21 depletion on the biologic characteristics of CNE2 cells were detected through CCK-8, Transwell Invasion Assay and flow cytometry. Mechanistic studies were based on bioinformatic analysis and immunoblotting.
RESULTS: A CRISPR/Cas9 system with targeted knockdown of miR-21 gene was obtained. miR-21 depletion evidently inhibited the growth, clone formation, and invasion as well as migration abilities of CNE2 cells, thus inducing apoptosis. A total of 28 KEGG were identified through the bioinformatic analysis. Further immunoblotting showed that the expressions of proteins involved in the PI3K/AKT/mTOR signaling pathway were decreased in response to miR-21 depletion.
CONCLUSIONS: miR-21 depletion can suppress the cell growth as well as proliferation and induce apoptosis in CNE2 cells possibly by inhibiting the PI3K/AKT/mTOR signaling pathway. IJCEP
Copyright © 2020.

Entities:  

Keywords:  CNE2; CRISPR/Cas9; microRNA 21; nasopharyngeal carcinoma

Year:  2020        PMID: 32355522      PMCID: PMC7191151     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  Downregulation of microRNA-21 enhances radiosensitivity in nasopharyngeal carcinoma.

Authors:  Honghai Zhu; Xiaoyuan Zhu; Genyang Cheng; Minghui Zhou; Weihua Lou
Journal:  Exp Ther Med       Date:  2015-04-02       Impact factor: 2.447

Review 2.  CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.

Authors:  Hasan Mollanoori; Hojat Shahraki; Yazdan Rahmati; Shahram Teimourian
Journal:  Hum Immunol       Date:  2018-09-24       Impact factor: 2.850

Review 3.  Applications and advances of CRISPR-Cas9 in cancer immunotherapy.

Authors:  An-Liang Xia; Qi-Feng He; Jin-Cheng Wang; Jing Zhu; Ye-Qin Sha; Beicheng Sun; Xiao-Jie Lu
Journal:  J Med Genet       Date:  2018-07-03       Impact factor: 6.318

Review 4.  Nasopharyngeal carcinoma: understanding its molecular biology at a fine scale.

Authors:  Prosenjit Paul; Himangshu Deka; Arup K Malakar; Binata Halder; Supriyo Chakraborty
Journal:  Eur J Cancer Prev       Date:  2018-01       Impact factor: 2.497

Review 5.  MicroRNA-21 is a novel promising target in cancer radiation therapy.

Authors:  Jia Liu; Hongcheng Zhu; Xi Yang; Yangyang Ge; Chi Zhang; Qin Qin; Jing Lu; Liangliang Zhan; Hongyan Cheng; Xinchen Sun
Journal:  Tumour Biol       Date:  2014-01-21

Review 6.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  EMBO Mol Med       Date:  2012-02-20       Impact factor: 12.137

7.  Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene.

Authors:  Hesheng Ou; Yumei Li; Min Kang
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 8.  What is CRISPR/Cas9?

Authors:  Melody Redman; Andrew King; Caroline Watson; David King
Journal:  Arch Dis Child Educ Pract Ed       Date:  2016-04-08       Impact factor: 1.309

9.  Antisense Oligonucleotides against miR-21 Inhibit the Growth and Metastasis of Colorectal Carcinoma via the DUSP8 Pathway.

Authors:  Tao Ding; Panpan Cui; Ya Zhou; Chao Chen; Juanjuan Zhao; Hairong Wang; Mengmeng Guo; Zhixu He; Lin Xu
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-13       Impact factor: 8.886

Review 10.  CRISPR/Cas9 Immune System as a Tool for Genome Engineering.

Authors:  Magdalena Hryhorowicz; Daniel Lipiński; Joanna Zeyland; Ryszard Słomski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-10-03       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.